NasdaqGM - Delayed Quote ? USD Denali Capital Acquisition Corp. (DECA) Follow Compare 11.51 0.00 (0.00%) At close: October 4 at 4:00 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion Semnur is currently in discussions regarding strategic regional and/or worldwide collaborations and potential outright acquisition of SP-102. Any such transactions may have the potential to provide value in excess of $2.5 billion after the proposed business combination (the “Business Combination”) with Denali Capital Acquisition Corp. (Nasdaq: DECA, the “SPAC”).Based on an independent market research conducted by Syneos Health Consulting (“Syneos”), with the substantial intent in utilization for GlobeNewswire ? 21 hours ago DECA 0.00% DECAU DECAW Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination NEW YORK, NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ: DECA) (the “Company”) announced today that it has deposited into the Company’s trust account (the “Trust Account”) an aggregate of $15,063.74 to fund the one-month extension from October 11, 2024, to November 11, 2024. This deposit was funded via a convertible promissory note with a principal amount of up to $180,000 issued by the Company to Scilex Holding Company (Nasdaq: SCLX, “Scilex”), which bears GlobeNewswire ? 5 days ago DECA 0.00% DECAU DECAW Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination, Providing for a Pre-Transaction Equity Value of Semnur of $2.5 Billion Semnur Pharmaceuticals, Inc. (“Semnur”), a wholly owned subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. (Nasdaq: DECA, the “SPAC”) announce the signing of an agreement and plan of merger for a proposed business combination (the “Business Combination Agreement”), which provides for a pre-transaction equity value of Semnur of $2.5 billion. The Board of Scilex, Semnur, and Denali Capital Acquisition Corp. have approved the proposed transaction.The GlobeNewswire ? last month SCLX SCLXW DECA 0.00% Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination Semnur Pharmaceuticals, Inc. (“Semnur”), a wholly owned subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. (Nasdaq: DECA, the “SPAC”) announce the signing of an agreement and plan of merger for a proposed business combination (the “Business Combination Agreement”), which provides for a pre-transaction equity value of Semnur of $2.5 billion. The Board of Scilex, Semnur, and Denali Capital Acquisition Corp. have approved the proposed transaction. Th GlobeNewswire ? last month SCLX SCLXW DECA 0.00% Denali Capital Acquisition Corp. Announces Shareholder Approval of Extension of Deadline to Complete Business Combination NEW YORK, NEW YORK, July 10, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ: DECA) (the “Company”) announced today that the Company’s shareholders voted in favor of approving amendments to the Company’s amended and restated memorandum and articles of association (the “Articles”) to extend the date by which the Company must consummate an initial business combination from July 11, 2024 to April 11, 2025 by electing to extend the date to consummate an initial business combination GlobeNewswire ? 3 months ago DECA 0.00% DECAU DECAW Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business Combination Semnur Pharmaceuticals, Inc. (“Semnur”), a wholly owned subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. (Nasdaq: DECA) (“SPAC”) announce signing of a letter of intent for a proposed business combination, which provides for a pre-transaction equity value of Semnur of up to $2.0 billion, subject to adjustment based on third-party fairness opinion, with expected cash on hand at closing of up to $40 million depending on the number of SPAC shares th GlobeNewswire ? 3 months ago DECA 0.00% DECAU DECAW Correction: Denali Capital Acquisition Corp. and Longevity Biomedical, Inc. Mutually Agreed to Terminate the Business Combination NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ: DECA) ("Denali" or the "Company") announced today that Denali and Longevity Biomedical, Inc. have mutually agreed to terminate their previously announced business combination agreement (the “Business Combination Agreement”). The Company and its sponsor intend to seek alternative ways to consummate an initial business combination. About Denali Capital Acquisition Corp. Denali Capital Acquisition Corp. is a blank GlobeNewswire ? 3 months ago DECA 0.00% DECAU DECAW Top Midday Gainers Top Midday Gainers PREMIUM MT Newswires ? 3 months ago NLSPW DECAW Denali Capital Acquisition Corp. and Longevity Biomedical, Inc. Mutually Agreed to Terminate the Business Combination NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ: DECA) ("Denali" or the "Company") announced today that Denali and Longevity Biomedical, Inc. have mutually agreed to terminate their previously announced business combination agreement (the “Business Combination Agreement”). The Company and its sponsor intend to seek alternative ways to consummate an initial business combination. About Denali Capital Acquisition Corp. Denali Capital Acquisition Corp. is a blank GlobeNewswire ? 3 months ago DECA 0.00% DECAU DECAW Denali Capital Acquisition Corp. Announces Postponement of Extraordinary General Meeting From Thursday, January 4, 2024 to Tuesday, January 9, 2024 Denali Capital Acquisition Corp. (Nasdaq: DECA) (the "Company") announced today that its previously announced extraordinary general meeting (the "Shareholder Meeting") originally scheduled for Thursday, January 4, 2024, at 9:00 AM, Eastern Time, is being postponed to Tuesday, January 9, 2024, at 9:00 AM, Eastern Time (the "Postponement"). There is no change to the physical location, the record date, the purpose or any of the proposals to be acted upon at the Shareholder Meeting. Shareholders may PR Newswire ? 9 months ago DECA 0.00% DECAU DECAW Performance Overview Trailing total returns as of 10/16/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return DECA S&P 500 YTD +13.18% +22.49% 1-Year +5.21% +35.00% 3-Year +15.68% +40.42%
